Board of Directors

Current Members:


Allen B. Reitz, Ph.D., Chair and Founding Member: Dr. Reitz is Foundation Distinguished Professor of the Institute for Hepatitis and Virus Research (IHVR). He appoints and chairs the due diligence teams to evaluate the technology for development and create target product profiles. Dr. Reitz has three decades of experience in the area of medicinal chemistry, including 26 years with Johnson & Johnson.  He led the medicinal chemistry efforts in the area of diseases of the central nervous system for 16 years at the Spring House, PA, facility, accounting for the introduction of seven new drug candidates into human clinical evaluation. He has 45 issued U.S. patents and 130 scientific publications.  In addition, Dr. Reitz is the Founding Editor of Current Topics in Medicinal Chemistry (www.bentham.org/ctmc), a highly regarded professional journal. He is experienced in the area of translational drug discovery as a scientist and recognized expert in the field.  [link to LinkedIn page]

   

Kathleen M. Czupich, MBA, Founding Member: Ms. Czupich has over 20 years experience in business development and was the founding administrator for the IHVR and the PA Biotech Center. Ms. Czupich managed the financial and administrative aspects of the $7.9 million grant to construct the PA Biotech Center (PBC) and the resulting building project totaling more than $14 million. She was also instrumental in the negotiation, financing and purchase of the adjacent building, expanding the PBC to 115,000 square feet. Currently, in her role as Director of the PDDI, Ms. Czupich works on business development, grants administration, and management for early-stage technology-based businesses.  [link to LinkedIn page]

   

Bruce E. Maryanoff, Ph.D., Professor of Chemical Biology and Chair of the Scientific Advisory Board: Dr. Maryanoff is also Foundation Distinguished Professor of the Institute for Hepatitis and Virus Research; Investigator, The Scripps Research Institute-La Jolla; and Associate Editor, ACS Medicinal Chemistry Letters. He retired from Johnson & Johnson after 36 years of service in the field of medicinal chemistry, having led drug discovery research mainly in central nervous system and cardiovascular areas.  This activity resulted in 23 compounds entering preclinical development, 13 of which advanced to human clinical studies. Dr. Maryanoff discovered TOPAMAX (topiramate), a billion-dollar drug that is useful for the treatment of epilepsy and migraine.  He has published 275 scientific papers and is an inventor on 100 U.S. patents (issued or pending); has received three American Chemical Society (ACS) national awards and the 2009 Edward E. Smissman Award; and was inducted into the ACS Division of Medicinal Chemistry Hall of Fame in 2008.  He was elected Fellow in the ACS (inaugural class), American Association for the Advancement of Science, and the Royal Society of Chemistry.  [link to LinkedIn page]

Joseph F. Aceto, Ph.D, Esq., Attorney at Law and Counsel at Obermayer Rebmann Maxwell and Hippel: Dr. Aceto graduated from Temple University with a Ph.D. in pharmacology and from Widener University with a J.D. in law. He is a registered Intellectual Property attorney and is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office. His private practice involves primarily patent prosecution and licensing, working extensively with biotech and pharmaceutical companies, universities, and non-profit research institutions. He has worked with individual inventors, partnerships, and companies in securing patent protection and establishing a portfolio around new pharmaceuticals, medical devices, and diagnostics. Dr. Aceto is also Of Counsel at Obermayer Rebmann Maxwell and Hippel where he assists companies in establishing and securing copyright and trademark protection.  [link to LinkedIn page]


Paul S. Anderson, Ph.D., Senior Vice President, DuPont-Merck (ret.): Dr. Anderson received a B.S. in chemistry from the University of Vermont in 1959 and a Ph.D. in chemistry from the University of New Hampshire in 1963. After postdoctoral work at Cornell University, he joined Merck Sharp & Dohme Research Laboratories where he rose through the ranks to become Vice President for Chemistry at West Point, PA. In 1994, he retired from Merck to become the Senior Vice President for Chemical and Physical Sciences at the DuPont-Merck Pharmaceuticals Company (later DuPont Pharmaceuticals Company). In 1997 Dr. Anderson served as President of the American Chemical Society (ACS). He received the E. B. Herschberg Award for important discoveries in medicinally-active substances from the ACS in 1995. He received a Doctor of Science Honoris Causa from the University of Vermont and a Doctor of Chemistry Honoris Causa from the University of New Hampshire. Dr. Anderson was recipient of the ACS Award in Industrial Chemistry in 2001, the Perkin Medal in 2002 and the National Academy of Sciences Award for Chemistry in Service to Society in 2003. In 2006, the ACS recognized Dr. Anderson with its highest honor, the Priestley Medal.  [link to LinkedIn page]

 

Dennis Gross, Ph.D., Associate Dean and Director, College of Graduate Studies, Thomas Jefferson University: Dr. Gross is also Associate Professor of Pharmacology and Experimental Therapeutics in  Jefferson Medical College. He received B.A and M.S. degrees in biology from California State University, Northridge and a Ph.D. in cell biology from UCLA; he conducted postdoctoral studies at Tulane University School of Medicine. Dr. Gross joined Merck Sharp & Dohme Research Labs in 1977 and held several positions of increasing responsibility in his 28-year career: bench scientist, head of computer resources, manager of international strategic planning, and liaison for research and clinical drug development in Japan. As Senior Director for Business Operations and Planning, he was responsible for global, multisite operations at Merck. He has served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University and has worked with the Center for Strategic and International Studies on policy issues relating to biological WMD. Dr. Gross assumed his current role in 2006 and is responsible for four professional science master’s degree programs and two graduate certificates in biomedical sciences.  [link to LinkedIn page]


Bashar Hanna, Ph.D., Vice President for Academic Affairs and Dean of the Faculty, Delaware Valley College: Dr. Hanna serves as the Vice President for Academic Affairs and Dean of the Faculty at Delaware Valley College. Prior to joining Del-Val, he was the Associate Provost at Ithaca College. He served as Dean of the College of Liberal Arts and Sciences and Interim Provost at Kutztown University. Dr. Hanna earned his doctorate in Developmental Neurobiology from Temple University. He has taught undergraduate and graduate courses in Biology, Neurobiology, Aging Studies and Mathematics. Dr. Hanna started his career at Temple University, where he held multiple positions including Assistant Vice Provost for Research and Sponsored Projects and Associate Dean of the College of Science in Technology.


Ned D. Heindel, Ph.D., Howard S. Bunn Chair Professor, Lehigh University: Dr. Heindel received a B.S. in chemistry at Lebanon Valley College in 1959 and a Ph.D. from the University of Delaware in 1963. After an NSF Postdoctoral Fellowship at Princeton University, he joined the faculties of Marshall University and Ohio University. In 1966 he relocated to Lehigh University where his research has involved the development of diagnostic and therapeutic products. Dr. Heindel has consulted in big and small pharma, and has mentored 41 doctoral students, 147 M.S. students, and 27 postdoctoral fellows, most of whom have undertaken careers inside the pharmaceutical industry. He has served on 2 corporate boards, 5 scientific advisory boards, 3 editorial boards, 4 professional boards, and 2 government commissions. He directs the medicinal chemistry research program of Azevan Pharmaceuticals and the drug development program for Project CounterACT-Rutgers, a federal program seeking antidotes for sulfur mustard poisoning. In 1994 Dr. Heindel served as President of the American Chemical Society (ACS). He holds 11 patents and has published 282 papers. He received the NOBCChE-Henry Hill Award in medicinal chemistry, the Brady Foundation award for research in tumor-imaging radiopharmaceuticals, and the Hillman award for educational and research achievements. In 2009 he was named a Fellow of the ACS.  [link to LinkedIn page]


Donna M. Huryn, Ph.D., Professor of Chemistry, University of Pennsylvania: Dr. Huryn graduated with a Ph.D. in organic chemistry from the University of Pennsylvania. She spent 20 years in the pharmaceutical industry, at both Hoffmann-La Roche and Wyeth Research, where she directed the Neuroscience Medicinal Chemistry Department as well as the Chemical Sciences Interface Department.  In 2004 she joined academia with an appointment at the University of Pittsburgh School of Pharmacy.  She is now on the faculty of the University of Pennsylvania, Department of Chemistry.  [link to LinkedIn page]

   

Gregory F. Krug, President, Lampire Biological Laboratories, Inc.: Mr. Krug, founder of Lampire Biological Laboratories, has guided the company’s growth and development since its inception in 1977.  He completed acquisition of the corporation in 1979 and holds 100% ownership; he is responsible for the operation and financial performance of the company.  As Chief Executive officer, Mr. Krug has the ultimate responsibility for compliance with all federal, state, and local regulatory agencies.  As Institutional Official, Mr. Krug appoints the Institutional Animal Care and Use Committee (IACUC) to review, investigate and report all activities related to Animal Welfare in compliance with 9 CFR Chapter (Code of Federal Regulation). He is active in  professional associations and highly involved in the local community.  Mr. Krug received the Achievement Award in Animal Science for his accomplishments in the field from Delaware Valley College Alumni Association, the 2005 Entrepreneur Award by Pennsylvania Business Central, and 2006 Pennsylvania Small Business Exporter of the Year Award by the Small Business Administration.  [link to LinkedIn page]

 

Michael J. Zelesko, Ph.D., Vice President, Johnson & Johnson (ret.): Dr. Zelesko received a Ph.D. in organic chemistry from Princeton University in 1969, after which he joined McNeil Pharmaceutical (a Johnson & Johnson subsidiary) as a medicinal chemist. He worked for Johnson & Johnson for 30 years, finishing his career as Vice President of Discovery Research, U.S., in the Janssen Research Foundation. Over the years, research efforts of his team involved the discovery of new drugs to treat central nervous system disorders, HIV-AIDS, inflammation, and cancer, which led to several marketed products.  [link to LinkedIn page]



Alumni:


Dennis C. Liotta, Ph.D., Professor of Chemistry, Emory University: Dr. Liotta has extensive experience in multidisciplinary research and his laboratory is noted for its collaborative efforts that span a rich spectrum of academic departments. Over the past two and a half decades Dr. Liotta's research has focused on the discovery and development of novel antiviral, anticancer and antiinflammatory therapeutic agents. He is one of the leaders of the Emory team that developed the antiviral drug, FTC (Emtriva), which was approved for HIV in July 2003. In addition, he is the inventor of record for several clinically important antivirals, including 3TC (Epivir, lamivudine), D-D4FC (Reverset, DPC-817), Racivir (racemic FTC) and L-D4FC (elvucitabine). He is also the lead inventor of MSX-122, a safe, orally available clinical agent for treating cancer and inflammation.  [link to LinkedIn page]